Characterization of CD22 expression in acute lymphoblastic leukemia

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• CD22 is a key B-cell marker and a significant therapeutic target in acute lymphoblastic leukemia (ALL).
• Understanding CD22 expression is crucial for developing effective targeted therapies for ALL.

Purpose of the Study:

• To characterize CD22 expression properties in pediatric and young adult B-precursor (pre-B) ALL.
• To assess the suitability of CD22 as a therapeutic target in relapsed and refractory ALL.

Main Methods:

• Analysis of primary B-precursor ALL samples from children and young adults.
• Quantification of CD22 expression levels and antigen site density on blasts.
• Evaluation of CD22 expression in serial studies and in the presence of MLL rearrangement.

Main Results:

• CD22 was expressed on at least 90% of blasts in 155 out of 163 ALL cases.
• Median CD22 site density was 3,470 sites/cell, but lower in cases with MLL rearrangement (median 1,590 sites/cell).
• A subset of MLL-rearranged ALL cases exhibited CD22-negative blast subpopulations.

Conclusions:

• CD22 is a highly suitable therapeutic target for relapsed/refractory ALL.
• Close monitoring for CD22-negative blasts is essential in ALL cases with MLL rearrangement.